Literature DB >> 35699872

A survey of internists' recommendations for aspirin in older adults and barriers to evidence-based use.

Jordan K Schaefer1, Geoffrey D Barnes2, Jeremy B Sussman3,4, Sameer D Saini4,5, Tanner J Caverly4,6,5, Susan Read7, Brian J Zikmund-Fisher3,8,9, Jacob E Kurlander4,5.   

Abstract

Recent trials suggest that aspirin for primary prevention may do more harm than good for some, including adults over 70 years of age. We sought to assess how primary care providers (PCPs) use aspirin for the primary prevention in older patients and to identify barriers to use according to recent guidelines, which recommend against routine use in patients over age 70. We surveyed PCPs about whether they would recommend aspirin in clinical vignettes of a 75-year-old patient with a 10-year atherosclerotic cardiovascular disease risk of 25%. We also queried perceived difficulty following guideline recommendations, as well as perceived barriers and facilitators. We obtained responses from 372 PCPs (47.9% response). In the patient vignette, 45.4% of clinicians recommended aspirin use, which did not vary by whether the patient was using aspirin initially (p = 0.21); 41.7% believed aspirin was beneficial. Perceived barriers to guideline-based aspirin use included concern about patients being upset (41.6%), possible malpractice claims (25.0%), and not having a strategy for discussing aspirin use (24.5%). The estimated adjusted probability of rating the guideline as "hard to follow" was higher in clinicians who believed aspirin was beneficial (29.4% vs. 8.0%; p < 0.001) and who worried the patient would be upset if told to stop aspirin (26.7% vs. 12.5%; p = 0.001). Internists vary considerably in their recommendations for aspirin use for primary prevention in older patients. A high proportion of PCPs continue to believe aspirin is beneficial in this setting. These results can inform de-implementation efforts to optimize evidence-based aspirin use.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aspirin; Cardiovascular disease; Primary prevention; Surveys and questionnaires

Year:  2022        PMID: 35699872     DOI: 10.1007/s11239-022-02669-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  5 in total

1.  Primary care physicians' awareness and perceptions on adherence to primary cardiovascular disease prevention guidelines in Lebanon: A cross-sectional study.

Authors:  Zeina Halabi; Mona Osman; Reem Hoteit
Journal:  Chronic Illn       Date:  2020-12-29

Review 2.  Reducing the risk of adverse drug events in older adults.

Authors:  Richard W Pretorius; Gordana Gataric; Steven K Swedlund; John R Miller
Journal:  Am Fam Physician       Date:  2013-03-01       Impact factor: 3.292

Review 3.  Polypharmacy: Evaluating Risks and Deprescribing.

Authors:  Anne D Halli-Tierney; Catherine Scarbrough; Dana Carroll
Journal:  Am Fam Physician       Date:  2019-07-01       Impact factor: 3.292

4.  Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention.

Authors:  Michael Kolber; Nadder Sharif; Raelene Marceau; Olga Szafran
Journal:  Can Fam Physician       Date:  2013-01       Impact factor: 3.275

Review 5.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.